News

Cardiac monitoring has not been adequately established for such patients.

The new PDUFA date for the biologic has been scheduled for early 2022.

There was no evidence found suggesting children with lower emotion regulation ability at years old had greater probability of later reporting symptoms of broad anorexia nervosa.

A maternal-infant HCV linkage program in combination with a multidisciplinary clinic to collocate mother and infant care was implemented in 2016.

Dr. Manesh Patel shares perspective on the "renaissance of anti-thrombotic therapy" for patients at risk of cardiovascular events.

The overall serum anti-toxin A and B antibody levels were similar at baseline between immunocompromised hosts and non-immunocompromised hosts.

Investigators show that both terms tend to be used in different contexts within the biomedical literature.

Physicians who performed well on ABIM examination less likely to prescribe opioids for back pain compared to physicians who did not perform well.

Schuyler Jones, MD discusses risk stratification in CAD/PAD and treatments aimed at atherothrombosis.

Florian Thomas, MD, and Adrian Hepner, MD, cover the basics of the degenerative nerve disorder.

Growing evidence shows promise of stroke prevention with anti-thrombotic therapy in patients with AF.

Research shows that detailed systems of care for infants suffering with BPD are integral in managing the national rate of infection.

Telemedicine could be useful if it is added to regimen of in-person health care visits.

The new PDUFA date for avacopan has been pushed back to October 7.

The EMPEROR-Preserved trial demonstrated safety and efficacy of empagliflozin for patients with heart failure across spectrum of ejection fraction.

FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.

The study highlights the myriad of physical and emotional complications in young patients in the London area.

Patients included in the high-dose group demonstrated statistically significant improvements compared to placebo for MDS-UPDRS total score.

Cases were identified by searching the Veterans Affairs Corporate Data Warehouse.

An expert ophthalmologist offers lessons and insights into the rare genetic eye disorder.

Currently, there are no glaucoma-specific instruments that estimate utilities across the spectrum of glaucoma severity.

Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Mortality rates differed significantly across the 3 clusters.

Investigators say that dietary habits in youth and young adult patients with diabetes can be impacted by income, employment, ethnicity, and a variety of other factors.

Methylphenidate hydrochloride (Adhansia XR) was originally approved in 2019 for ADHD patients at least 6 years old.

The treatment resulted in a significant reduction in expression of genes representing T & B lymphocytes, plasma cells/plasmablasts, and myeloid cells.

Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.